| Literature DB >> 33731690 |
Ashiq Masood1,2, Trevor Christ3,4, Samia Asif5, Priya Rajakumar6, Beth A Gustafson7, Leyla O Shune8, Ameen Salahudeen9, Drew Nedvad10, Suparna Nanua11, Agne Paner6, Timothy M Kuzel6, Mia Levy6, Janakiraman Subramanian7,12, Shahzad Raza12.
Abstract
Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of NSSM are not well characterized. Here, we report a case of a patient with relapsed and refractory NSMM with brain metastasis harboring a TFG-ALK fusion showing a dramatic and durable (over two years) response to commercially available anaplastic lymphoma kinase (ALK) inhibitors. The case emphasizes the beneficial role of molecular profiling in this target-poor disease.Entities:
Year: 2021 PMID: 33731690 PMCID: PMC7969947 DOI: 10.1038/s41525-021-00186-9
Source DB: PubMed Journal: NPJ Genom Med ISSN: 2056-7944 Impact factor: 8.617